We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2019 to May 2024
By Adam Clark
GlaxoSmithKline PLC (GSK.LN) said Thursday that it has submitted a regulatory application in Australia for the approval of a potential malaria treatment.
The pharmaceutical is seeking approval for single-dose tafenoquine to treat Plasmodium vivax malaria from Australia's Therapeutic Goods Administration. The submission includes phase 3 data from previous studies.
Getting the green light in Australia would open the way for approval in countries where the disease is endemic, said GSK, adding that it intends to make the treatment available at a not-for-profit price in such places.
The company said that tafenoquine isn't currently approved for use anywhere in the world, and that it intends to proceed with regulatory filings in other countries in 2018.
Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones
(END) Dow Jones Newswires
December 14, 2017 05:41 ET (10:41 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
